Get the Stockscreener App
4.40
3.53%
0.15
After Hours:
4.40
Omeros Corporation stock is traded at $4.40, with a volume of 310.21K.
It is up +3.53% in the last 24 hours and up +16.71% over the past month.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
See More
Previous Close:
$4.25
Open:
$4.22
24h Volume:
310.21K
Relative Volume:
1.19
Market Cap:
$254.97M
Revenue:
-
Net Income/Loss:
$-117.81M
P/E Ratio:
6.875
EPS:
0.64
Net Cash Flow:
$74.30M
1W Performance:
+2.56%
1M Performance:
+16.71%
6M Performance:
+17.96%
1Y Performance:
+243.75%
1-Day Range:
$4.22
$4.425
1-Week Range:
$4.01
$4.425
52-Week Range:
$1.13
$5.68
Omeros Corporation Stock (OMER) Company Profile
Name
Omeros Corporation
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corporation Stock (OMER) Latest News
Atypical Hemolytic Uremic Syndrome Drugs Market 2034: - openPR
NVIDIA Co. (NASDAQ:NVDA) Stock Holdings Increased by Alpha DNA Investment Management LLC - Defense World
Omeros (NASDAQ:OMER) Shares Pass Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Global Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Market to Reach USD 2308.84 Million by 20 - PharmiWeb.com
OMEROmeros Corporation Latest Stock News & Market Updates - StockTitan
FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy - Business Wire
Global Alcohol Use Disorder Treatment Market to Reach USD 1,300 million by 2033 at a 6.4% CAGR, Driv - PharmiWeb.com
Ischemia Reperfusion Injury Therapeutics Market Generated - openPR
Omer Arbel Office unveils planned community for Washington State site - The Architect's Newspaper
OMER (Omeros) Operating Margin % : 0.00% (As of Jun. 2024) - GuruFocus.com
PDE Inhibitors Market: Report Trends and Future Forecast Until (2024-2034) - IndiaPolitics.com
Metastatic Melanoma Drug Industry Size, Regional Demand, Trends and Forecast to (2024-2034) - Cineglit
China Gastrointestinal Stromal Tumor (GIST) Drug Market Research Covers, Future Trends and Deep Analysis (2024-2034) – IndiaPolitics.com - IndiaPolitics.com
Opioid Use Disorder (OUD) Market Report 2024: Growth, Trends, Competitive Outlook to 2033 - WhaTech
Mizrahi Tefahot lends Omer Adam's server farm co NIS 410m - Globes
Mydriasis Treatment Market: Company Profiles, Segment - openPR
Global PNH and aHUS Market Analysis 2024-2032: Trends, Drivers, Challenges, and Quantitative Insights - WICZ
Gastrointestinal Stromal Tumor (GIST) Drug Market Strategies and Forecast Till, (2024-2034) - உங்கள் குரல்
Nicotine Addiction Treatment Market Current Status and Future Prospects (2024-2029)-RTI International, Omeros Corporation, Heptares Therapeu – cineglit - Cineglit
Omeros (NASDAQ:OMER) Stock Price Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Metastatic Melanoma Drug Market In-Depth Analysis, Business Forecast and Dynamics 2023 – (2024-2034) - KnowCasino
IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, - openPR
IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, Pipeline, Medication, Therapies, Treatment Market and Companies by DelveInsight - Barchart
OMER Stock Falls 5.35% Amid Mixed Institutional Ratings - GuruFocus.com
Omeros (OMER) Shares Drop 5.04% Amid Financial Struggles - GuruFocus.com
PNH and aHUS Market 2024 – Key Regions, Company Profile, Opportunity and Challenge 2032 | Omeros Corporation, RA Pharmaceuticals - 대구포스트
Relieved Omer Riza wants to grab 'great opportunity' after overseeing first Cardiff City win - Wales Online
Global Nicotine Replacement Therapy Market is Predicted to - GlobeNewswire
Orex Minerals Welcomes New CEO and Board Member - TipRanks
SVP, Merchandising McLain Kevin sale 15,000 shares of Ollies Bargain Outlet Holdings Inc [OLLI] - Knox Daily
Orrstown Financial Services (NASDAQ:ORRF) Reaches New 1-Year High at $36.65 - MarketBeat
Middleton & Co. Inc. MA Decreases Stake in O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
Altria Group (NYSE:MO) Stock Price Down 0.3% - MarketBeat
Meiji Yasuda Asset Management Co Ltd. Boosts Stock Position in Omnicom Group Inc. (NYSE:OMC) - Defense World
Kendall Capital Management Has $7.22 Million Stake in Omnicom Group Inc. (NYSE:OMC) - Defense World
Altrius Capital Management Inc Has $4.63 Million Holdings in Altria Group, Inc. (NYSE:MO) - Defense World
The growth track for OneMain Holdings Inc (OMF) has changed recently - SETE News
Vanguard Personalized Indexing Management LLC Boosts Holdings in O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
Garner Asset Management Corp Grows Position in Old Republic International Co. (NYSE:ORI) - Defense World
Axxcess Wealth Management LLC Trims Stake in O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
Optimist Retirement Group LLC Cuts Stock Position in Omnicom Group Inc. (NYSE:OMC) - Defense World
Market Insight: Omnicell, Inc. (OMCL)’s Notable Drop, Closing at 42.78 - The Dwinnex
Optimist Retirement Group LLC Boosts Stock Position in Altria Group, Inc. (NYSE:MO) - Defense World
Omnicom Group Inc. (NYSE:OMC) Position Increased by Sienna Gestion - Defense World
Meiji Yasuda Asset Management Co Ltd. Purchases 84,312 Shares of Altria Group, Inc. (NYSE:MO) - Defense World
Oram Awards announces 2024 winners, celebrating women, trans, non-binary and gender expansive musicians - DJ Mag
Omnicell, Inc.: Navigating a Turbulent Year, Up -23.68% from 52-Week Low - The InvestChronicle
Bradley Foster & Sargent Inc. CT Reduces Stake in Omnicom Group Inc. (NYSE:OMC) - Defense World
Omnicom Group (NYSE:OMC) Sets New 1-Year High at $102.75 - Defense World
Moors & Cabot Inc. Buys 164 Shares of O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
Roper Technologies, Inc. (NYSE:ROP) Shares Sold by Inspire Investing LLC - Defense World
Omeros Corporation Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
Omeros Corporation Stock (OMER) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Demopulos Peter A MD | Director |
Nov 15 '23 |
Buy |
1.53 |
10,000 |
15,300 |
208,516 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):